Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Tyck till om SwePub Sök här!

Search: WFRF:(Ponikowski Piotr) > Cleland John G. F. > Li Jing > Cardiac Myosin Acti...

1 of 1
Previous record
Next record
To hitlist

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

Teerlink, John R. (author): San Francisco VA Med Ctr, CA 94143 USA; Univ Calif San Francisco, CA 94143 USA

Diaz, Rafael (author): Estudios Clin Latino Amer, Argentina

Felker, G. Michael (author): Duke Univ, NC 27706 USA; Duke Clin Res Inst, NC USA; Natl & Kapodistrian Univ Athens, Greece

McMurray, John J. V. (author): British Heart Fdn, England

Metra, Marco (author): Univ Brescia, Italy

Solomon, Scott D. (author): Brigham & Womens Hosp, MA 02115 USA

Adams, Kirkwood F. (author): Univ N Carolina, NC 27515 USA

Anand, Inder (author): Univ Minnesota, MN USA

Arias-Mendoza, Alexandra (author): Inst Nacl Cardiol, Mexico

Biering-Sorensen, Tor (author): Univ Copenhagen, Denmark; Univ Copenhagen, Denmark

Bohm, Michael (author): Saarland Univ, Germany

Bonderman, Diana (author): Med Univ Vienna, Austria

Cleland, John G. F. (author): Univ Glasgow, Scotland; Imperial Coll, England; Univ Nova Lisboa, Portugal

Corbalan, Ramon (author): Pontificia Univ Catolicica Chile, Spain

Crespo-Leiro, Maria G. (author): Univ A Coruna, Spain

Dahlström, Ulf (author): Linköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Region Östergötland, Kardiologiska kliniken US

Echeverria, Luis E. (author): Fdn Cardiovasc & Colombia, Colombia

Fang, James C. (author): Univ Utah, UT USA

Filippatos, Gerasimos (author): National and Kapodistrian University of Athens, Attikon University Hospital, Greece; Athens, Greece

Fonseca, Candida (author): Hospital S. Francisco Xavier, Centro Hospitalar Lisboa Ocidental, NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal

Goncalvesova, Eva (author): Comenius Univ, Slovakia

Goudev, Assen R. (author): Queen Giovanna Univ Hosp & Med Univ, Bulgaria

Howlett, Jonathan G. (author): Univ Calgary, Canada

Lanfear, David E. (author): Henry Ford Hosp, MI 48202 USA

Li, Jing (author): Chinese Acad Med Sci & Peking Union Med Coll, Peoples R China

Lund, Mayanna (author): Middlemore Hosp, New Zealand

Macdonald, Peter (author): St Vincents Hosp Sydney, Australia

Mareev, Viacheslav (author): Moscow MV Lomonosov State Univ, Russia

Momomura, Shin-ichi (author): Saitama Citizens Med Ctr, Japan

OMeara, Eileen (author): Montreal Heart Inst, Canada; Univ Montreal, Canada

Parkhomenko, Alexander (author): Section of Cardiology, San Francisco Veterans Affairs Medical Center, School of Medicine, University of California, San Francisco, San Francisco, United States; Robertson Centre for Biostatistics and Clinical Trials, Institute of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom

Ponikowski, Piotr (author): Wroclaw Med Univ, Poland

Ramires, Felix J. A. (author): Univ Sao Paulo, Brazil

Serpytis, Pranas (author): Vilnius Univ, Lithuania

Sliwa, Karen (author): Univ Cape Town, South Africa

Spinar, Jindrich (author): St Ann Hosp, Czech Republic; Masaryk Univ Brno, Czech Republic

Suter, Thomas M. (author): Univ Bern, Switzerland

Tomcsanyi, Janos (author): St John God Hosp, Hungary

Vandekerckhove, Hans (author): AZ St Lucas, Belgium

Vinereanu, Dragos (author): Univ & Emergency Hosp, Romania

Voors, Adriaan A. (author): Univ Groningen, Netherlands

Yilmaz, Mehmet B. (author): Dokuz Eylul Univ, Turkey

Zannad, Faiez (author): Section of Cardiology, San Francisco Veterans Affairs Medical Center, School of Medicine, University of California, San Francisco, San Francisco, United States; Fundación Cardiovascular de Colombia, Floridablanca, Colombia

Sharpsten, Lucie (author): Amgen Inc, CA USA

Legg, Jason C. (author): Amgen Inc, CA USA

Varin, Claire (author): Univ Lorraine, France

Honarpour, Narimon (author): Amgen Inc, CA USA

Abbasi, Siddique A. (author): Amgen Inc, CA USA

Malik, Fady I. (author): Cytokinetics, CA USA

Kurtz, Christopher E. (author): Amgen Inc, CA USA

show less...

(creator_code:org_t)

Waltham, MA, United States : MASSACHUSETTS MEDICAL SOC, 2021
2021
English.
In: New England Journal of Medicine. - Waltham, MA, United States : MASSACHUSETTS MEDICAL SOC. - 0028-4793 .- 1533-4406. ; 384:2, s. 105-116

Related links:: https://urn.kb.se/re...; show more...; https://doi.org/10.1...; show less...

Journal article (peer-reviewed)

Abstract Subject headings

Among patients with heart failure and a reduced ejection fraction, those who received the cardiac myosin activator omecamtiv mecarbil had a lower incidence of a composite of heart-failure events or cardiovascular death at a median of 22 months than those who received placebo. Background The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. Methods We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The primary outcome was a composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes. Results During a median of 21.8 months, a primary-outcome event occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P=0.03). A total of 808 patients (19.6%) and 798 patients (19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11). There was no significant difference between groups in the change from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom score. At week 24, the change from baseline for the median N-terminal pro-B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and ventricular arrhythmia events was similar in the two groups. Conclusions Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, ; EudraCT number, 2016-002299-28.)

Find in a library

New England Journal of Medicine (Search for host publication in LIBRIS)

To the university's database

1 of 1
Previous record
Next record
To hitlist

Find more in SwePub

By the author/editor: Teerlink, John R ...; Diaz, Rafael; Felker, G. Micha ...; McMurray, John J ...; Metra, Marco; Solomon, Scott D ...; show more...; Adams, Kirkwood ...; Anand, Inder; Arias-Mendoza, A ...; Biering-Sorensen ...; Bohm, Michael; Bonderman, Diana; Cleland, John G. ...; Corbalan, Ramon; Crespo-Leiro, Ma ...; Dahlström, Ulf; Echeverria, Luis ...; Fang, James C.; Filippatos, Gera ...; Fonseca, Candida; Goncalvesova, Ev ...; Goudev, Assen R.; Howlett, Jonatha ...; Lanfear, David E ...; Li, Jing; Lund, Mayanna; Macdonald, Peter; Mareev, Viachesl ...; Momomura, Shin-i ...; OMeara, Eileen; Parkhomenko, Ale ...; Ponikowski, Piot ...; Ramires, Felix J ...; Serpytis, Pranas; Sliwa, Karen; Spinar, Jindrich; Suter, Thomas M.; Tomcsanyi, Janos; Vandekerckhove, ...; Vinereanu, Drago ...; Voors, Adriaan A ...; Yilmaz, Mehmet B ...; Zannad, Faiez; Sharpsten, Lucie; Legg, Jason C.; Varin, Claire; Honarpour, Narim ...; Abbasi, Siddique ...; Malik, Fady I.; Kurtz, Christoph ...; show less...

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Cardiac and Card ...

Articles in the publication: New England Jour ...

By the university: Linköping University

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

Subject headings

Publication and Content Type

Find in a library

To the university's database

Find more in SwePub

Search outside SwePub